These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11560013)

  • 1. [Mechanisms of glomerular autoimmunity and a strategy for immunomodulation in glomerular nephritis].
    Kolesnyk MO; Lapchyns'ka II
    Lik Sprava; 2001; (3):16-21. PubMed ID: 11560013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The concept of glomerular self-defense.
    Kitamura M; Fine LG
    Kidney Int; 1999 May; 55(5):1639-71. PubMed ID: 10231428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoids stimulate p21(CIP1) in mesangial cells and in anti-GBM glomerulonephritis.
    Terada Y; Okado T; Inoshita S; Hanada S; Kuwahara M; Sasaki S; Yamamoto T; Marumo F
    Kidney Int; 2001 May; 59(5):1706-16. PubMed ID: 11318941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mediators of immune glomerular injury.
    Makker SP
    Am J Nephrol; 1993; 13(5):324-36. PubMed ID: 8116685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease.
    Reynolds J; Moss J; Duda MA; Smith J; Karkar AM; Macherla V; Shore I; Evans DJ; Woodrow DF; Pusey CD
    J Pathol; 2003 May; 200(1):118-29. PubMed ID: 12692850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions.
    Topham PS; Haydar SA; Kuphal R; Lightfoot JD; Salant DJ
    Kidney Int; 1999 May; 55(5):1763-75. PubMed ID: 10231439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cyclin kinase inhibitor p21CIP1/WAF1 limits glomerular epithelial cell proliferation in experimental glomerulonephritis.
    Kim YG; Alpers CE; Brugarolas J; Johnson RJ; Couser WG; Shankland SJ
    Kidney Int; 1999 Jun; 55(6):2349-61. PubMed ID: 10354282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement deposition in glomerular diseases.
    di Belgiojoso GB; Tarantino A; Durante A; Guerra L
    Proc Eur Dial Transplant Assoc; 1975; 11():515-21. PubMed ID: 1105561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum and glomerular complement in 205 cases of glomerulonephritis.
    Durante A; Rovati C; di Belgiojoso GB; Minetti L
    Proc Eur Dial Transplant Assoc; 1976; 12():189-96. PubMed ID: 935112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury.
    Allen AR; McHale J; Smith J; Cook HT; Karkar A; Haskard DO; Lobb RR; Pusey CD
    J Immunol; 1999 May; 162(9):5519-27. PubMed ID: 10228033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-glomerular basement membrane antibody-induced experimental glomerulonephritis: evidence for dose-dependent, direct antibody and complement-induced, cell-independent injury.
    Boyce NW; Holdsworth SR
    J Immunol; 1985 Dec; 135(6):3918-21. PubMed ID: 4067309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory interactions between inducible nitric oxide synthase and eicosanoids in glomerular immune injury.
    Lianos EA; Guglielmi K; Sharma M
    Kidney Int; 1998 Mar; 53(3):645-53. PubMed ID: 9507210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of immunoglobulin G anti-glomerular basement membrane antibodies eluted from kidneys of patients with glomerulonephritis. II. IgG subtypes and in vitro complement fixation.
    McPhaul JJ; Dixon FJ
    J Immunol; 1971 Sep; 107(3):678-84. PubMed ID: 4999091
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical course of lupus nephritis: relationship to the renal histologic findings.
    Pollak VE; Pirani CL; Dujovne I; Dillard MG
    Perspect Nephrol Hypertens; 1973; 1 Pt 2(0):1167-81. PubMed ID: 4139685
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of glomerular diseases of primary and secondary origin.
    O'Meara YM; Salant DJ
    Curr Opin Nephrol Hypertens; 1992 Oct; 1(1):124-32. PubMed ID: 1365824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation.
    Shankland SJ; Eitner F; Hudkins KL; Goodpaster T; D'Agati V; Alpers CE
    Kidney Int; 2000 Aug; 58(2):674-83. PubMed ID: 10916090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of serological studies of the complement system in glomerulonephritis].
    Szewczyk Z; Klinger M; Strychowski J
    Pol Tyg Lek; 1982 Aug; 37(29-30):869-73. PubMed ID: 6218487
    [No Abstract]   [Full Text] [Related]  

  • 18. Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis.
    Ooi JD; Li M; Kourkoutzelos K; Yagita H; Azuma M; Holdsworth SR; Kitching AR
    Nephrology (Carlton); 2015 Dec; 20(12):892-8. PubMed ID: 26043977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum levels and glomerular deposits of some components of complement in glomerular diseases. Correlations in 172 cases].
    Rovati C; Barbiano di Belgiojoso G; Durante A; Minetti L
    Minerva Nefrol; 1975; 22(6):252-61. PubMed ID: 1223702
    [No Abstract]   [Full Text] [Related]  

  • 20. [Primary glomerular disease--immunopathological studies and therapy].
    Hatano M
    Nihon Naika Gakkai Zasshi; 1983 Nov; 72(11):1485-501. PubMed ID: 6373978
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.